The ASCO Annual Meeting is one of the largest medical congresses in the world, with over 30,000 oncology professionals expected to attend and discuss the latest ground-breaking oncology research. This year, the theme of the meeting is “Illumination & Innovation: Transforming data into learning” and fully reflects Roche’s approach to innovation in diagnostics and pharmaceutical development in the pursuit of new healthcare solutions and better long term outcomes for people with cancer.
More than 300 abstracts outlining the latest data on 10 approved Roche cancer medicines and 10 investigational medicines have been accepted for presentation during the congress. Highlights include data in a number of different types of lung cancer and first results of our investigational immunotherapy. This body of clinical research demonstrates the strength of Roche’s oncology pipeline; particularly in cancer immunotherapy and personalised medicine, and our continuing commitment to improve outcomes for people with cancer.
Alongside our data, Roche looks forward to engaging with healthcare professionals and other stakeholders at and around ASCO 2015 on many topical issues around cancer care.